Tohoku J. Exp. Med., 2014 October, 234(2)
The Glu504Lys Polymorphism of Aldehyde Dehydrogenase 2 Contributes to Development of Coronary Artery Disease
FENG XU,1,2 YANING SUN,3 RUI SHANG,1,2 MINGHUA LI,1,2 LIANQUN CUI,3 ZHAOQIANG CUI2 and YUGUO CHEN1,2
1Department of Emergency and Chest Pain Center, Qilu Hospital, Shandong University, Ji'nan, Shandong, P.R. China
2The Key Laboratory of Emergency and Critical Care Medicine affiliated to Health Commission of Shandong Province, and Institute of Emergency and Critical Care Medicine, Qilu Hospital, Shandong University, Ji'nan, Shandong, P.R. China
3Department of Cardiology, Shandong Provincial Hospital, Shandong University, Ji'nan, Shandong, P.R. China
Coronary artery disease (CAD) is a leading cause of death, and its genetic mechanism has been always a major research concern. Recently, increasing evidence has indicated that the aldehyde dehydrogenase 2 (ALDH2) polymorphism, known as Glu504Lys (rs671), may contribute to CAD development. ALDH2 has been well known as a key enzyme in alcohol metabolism, and subjects with *504Lys allele exist in 30-50% of the East Asian population (6% of the world's population). However, recent studies have indicated that the *504Lys allele of the ALDH2 gene may be associated with the pathogenesis of CAD in a given number of Chinese, Japanese, and Korean people. This discovery has been further confirmed by a genome-wide association study in 2012 that identified the link of ALDH2 Glu504Lys polymorphism to CAD susceptibility. ALDH2 may therefore serve as an important target for CAD intervention. Several studies have suggested that ALDH2 polymorphism plays an important role in the progress of CAD through multiple mechanisms, including the regulation of alcohol consumption, inflammation, endothelial progenitor cells, oxidative stress, asymmetric dimethylarginine, endothelial nitric oxide synthase, and other CAD-promoting factors. Furthermore, the ALDH2 Glu504Lys polymorphism has been shown to be associated with certain traditional cardiovascular risk factors, such as dyslipidemia, hypertension, and diabetes mellitus or hyperglycemia. In this review, we update the current research on the association of the Glu504Lys polymorphism with the susceptibility to CAD. We also highlight and discuss the underlying mechanisms, by which the ALDH2 Glu504Lys polymorphism may be targeted for the prevention and treatment of CAD.
Key words —— aldehyde dehydrogenase 2; coronary artery disease; Glu504Lys polymorphism; mechanisms; susceptibility gene
© 2014 Tohoku University Medical Press
Tohoku J. Exp. Med., 2014, 234, 143-150
Correspondence: Yuguo Chen, M.D., Ph.D., Department of Emergency and Chest Pain Center, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Ji'nan, Shandong 250012, P.R. China.